ClinicalTrials.gg
WithdrawnNCT06392841HARMONYUpdated Apr 8, 2026

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

A Phase 2 interventional study of Androgen Deprivation Therapy (ADT) and Niraparib/Abiraterone Acetate DAT in Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation and BRCA1 Gene Mutation, sponsored by Qian Qin. Withdrawn. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Qian Qin · Phase 2, Interventional, and Treatment

How we know · 7 judgments

Why this study was withdrawn
Funder withdrew funding.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies testing prednisone in Prostatic Neoplasms — 9 open to participants now, 17 under way, 1 of them phase 3. Prednisone · Prostatic Neoplasms.

Enrollment
70th of 73
0 · median 57
Started
2025
with 2 others
Phase 2
40 of 75
6 open now
Registered
69th of 75
by date

Among the 75 studies testing prednisone in Prostatic Neoplasms, this one is the 70th largest by enrollment of the 73 interventional ones that give a count, is one of 3 that started in 2025, is one of 40 in phase 2, and was the 69th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 75 studies testing prednisone in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About prednisone

Prednisone: first FDA approval 1955 (METICORTEN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies testing prednisone in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This is an open label, phase II trial in subjects with treatment naïve, metastatic hormone sensitive prostate cancer (mHSPC) with deleterious homologous recombination repair (HRR) alteration(s). These include pathologic alterations in BRCA 1/2, BRIP1, CHEK2, FANCA, PALB2, RAD51B, and/or RAD54L. A total of 64 people will be enrolled to the study.

03

Conditions studied

  • Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
  • Deleterious HRR Gene Mutation
  • BRCA1 Gene Mutation
  • BRCA2 Gene Mutation
  • BRIP1 Gene Mutation
  • CHEK2 Gene Mutation
  • FANCA Gene Mutation
  • PALB2 Gene Mutation
  • RAD51B Gene Mutation
  • RAD54L Gene Mutation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
  2. ≥ 18 years of age at the time of consent.
  3. Self-identify as Hispanic/Latino or non-Hispanic black racial/ethnic background.
  4. Performance Status of ≤ 2 within 30 days prior to registration.
  5. confirmed diagnosis of prostate adenocarcinoma.
  6. Deleterious HRR alteration(s) per any validated test, next generation sequencing (NGS) mutational analysis (tissue or liquid). These include BRCA 1/2, BRIP1, CHEK2, FANCA, PALB2, RAD51B, and/or RAD54L.
  7. Radiographic evidence of disease as per conventional CT or MRI of chest, abdomen pelvis and bone scan, according to version 1.1 criteria in subjects with and PCWG3 criteria for subjects with bone only disease (1, 2). Evidence of metastatic disease detected on Axumin or PSMA PET/CT will need confirmation on conventional CT or MRI/bone scans.
  8. Hormone sensitive, treatment naïve/minimally treated [first generation androgen receptor inhibitor (ARI) such as bicalutamide ≤ 45 days, ADT ± abiraterone acetate plus prednisone ≤ 45 days allowed]. Prior therapy for localized prostate cancer allowed (including but not limited to radiation therapy, prostatectomy, lymph node dissection ± ADT, must have been completed > 6 months prior to registration).
  9. Demonstrate adequate organ function as defined below. All screening labs to be obtained within 30 days prior to registration.

    • (Plt): ≥ 100 x 10\^9/L (Independent of transfusions for at least 28 days prior to registration)
    • (ANC): ≥ 1.5 x 10\^9/L (Independent of hematopoietic growth factors for at least 28 days prior to registration)
    • (Hgb): ≥ 9 g/dL (Independent of transfusions for at least 28 days prior to registration)
    • Creatinine: Estimated (eGFR) ≥ 30 mL/min
    • Total : ≤ 1.5 × or direct bilirubin ≤ 1 x ULN (For subjects with Gilbert's syndrome, if total bilirubin is >1.5 × ULN, measure direct and indirect bilirubin, and if direct bilirubin is ≤1.5 × ULN, subjects may be eligible.)
    • (AST): ≤ 3 × ULN
    • Alanine aminotransferase (ALT): ≤ 3 × ULN
    • Serum potassium: ≥ 3.5 mmol/L
  10. Males able to father a child who are sexually active with a female of must be willing to abstain from penile-vaginal intercourse or use an effective method(s) of .
  11. Able to swallow the study medication tablets whole.
  12. ≥ 12 months.
  13. As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study.

Exclusion criteria

Exclusion Criteria:

  1. Prostate cancer variants including predominant neuroendocrine features and/or predominant small cell carcinoma of the prostate are excluded.
  2. Prior treatment with the following is excluded: second generation ARIs such as apalutamide, enzalutamide, darolutamide, or other ARIs; oral ketoconazole as antineoplastic treatment for prostate cancer (allowed if total time on ketoconazole as prostate cancer-directed therapy is ≤ 10 days and discontinued prior to study treatment initiation); chemotherapy or immunotherapy for prostate cancer.
  3. Radiotherapy/radiopharmaceuticals within 2 weeks of registration.
  4. History of severe allergic anaphylactic reactions to niraparib/abiraterone acetate tablets or any of their .
  5. Current evidence of any medical condition that would make prednisone use .
  6. Long-term use of systemically administered (> 5mg of prednisone or the equivalent) during the study is not allowed (5mg of prednisone or equivalent daily, given with abiraterone acetate, is allowed). Short-term use of corticosteroid for indication other than in combination with abiraterone acetate (≤ 4 weeks, including taper) and locally administered steroids (eg, inhaled, topical, ophthalmic, and intra-articular) are allowed, if clinically indicated.
  7. Subjects who have had major surgery ≤ 28 days prior to registration.
  8. Symptomatic .
  9. Active or symptomatic viral hepatitis or chronic liver disease; encephalopathy, ascites, or bleeding disorders secondary to hepatic dysfunction.
  10. Moderate or severe hepatic impairment (Class B and C per classification system.
  11. History of adrenal insufficiency not adequately managed.
  12. History or current diagnosis of MDS/AML.
  13. Current evidence within 6 months prior to registration of any of the following:

    • Severe/unstable angina, myocardial infarction, symptomatic congestive heart failure,
    • arterial or venous thromboembolic events (ie. pulmonary embolism), or clinically significant ventricular arrhythmias.
  14. Presence of sustained uncontrolled hypertension (systolic blood pressure >160 mm Hg or diastolic blood pressure >100 mm Hg). Subjects with a history of hypertension are allowed, provided that blood pressure is controlled to within these limits by an antihypertensive treatment.
  15. positive subjects with 1 or more of the following:

    • Not receiving highly active antiretroviral therapy or on antiretroviral therapy for less than 4 weeks.
    • Receiving antiretroviral therapy that may interfere with the study medication
    • \<350 at screening.
    • An acquired immunodeficiency syndrome-defining opportunistic infection within 6 months of the start of screening.
    • Human immunodeficiency virus load >400 copies/mL.
  16. Active infection requiring systemic therapy. NOTE: Subjects receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or exacerbation) are eligible for the study.
  17. Active (ie, progressing or requiring treatment change in the last 24 months) other than the disease being treated under study. The only allowed exceptions are:

    • Non-muscle invasive bladder cancer.
    • Skin cancer (non-melanoma or melanoma) treated within the last 24 months that is considered completely cured.
    • Malignancy that is considered cured with minimal risk of recurrence.
  18. Received an investigational intervention (including investigational vaccines) or used an invasive investigational medical device within 30 days prior to C1D1.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Initial Treatment (Cycle 1 to Cycle 6)

    Androgen Deprivation Therapy (ADT) with a GnRH agonist or antagonist per standard of care. 200 mg niraparib and 1,000 mg abiraterone acetate dual action tablet (DAT, Akeega) once daily, with 5mg prednisone once daily for 24 weeks (6 cycles) unless there is progression or unacceptable toxicity. After 6 cycles, disease evaluation performed.

    Drug: Androgen Deprivation Therapy (ADT) · Drug: Niraparib/Abiraterone Acetate DAT · Drug: Prednisone

  • Experimental
    Cohort A: prostate specific antigen (PSA) >4 ng/mL without progression at the completion of 24 weeks

    After 6 cycles, there will be an option to: 1. Continue ADT + niraparib/abiraterone acetate plus prednisone in 28-day cycles for a total of 2 years OR until disease progression or unacceptable toxicity. Subsequent therapy will be at the discretion of the investigator per standard of care. 2. Discontinue niraparib. Continue ADT, start abiraterone acetate plus prednisone and docetaxel 75mg/m2 in 21-day cycles. Docetaxel every 3 weeks x 6 doses. At the completion of docetaxel, the subject will move to follow-up per protocol. Niraparib should not be restarted at the completion of docetaxel. Subsequent therapy will be at the discretion of the investigator per standard of care.

    Drug: Androgen Deprivation Therapy (ADT) · Drug: Niraparib/Abiraterone Acetate DAT · Drug: Abiraterone Acetate · Drug: Prednisone · Drug: Docetaxel

  • Experimental
    Cohort B: PSA ≤ 4 ng/mL without progression at the completion of 24 weeks

    Continue ADT + niraparib/abiraterone acetate plus prednisone for 1 year unless progression or unacceptable toxicity. At 1 year, disease evaluation will occur. * PSA ≥ 0.2 ng/mL: ADT + niraparib/abiraterone acetate plus prednisone will continue for 2 years or until progression or unacceptable toxicity. Therapy beyond 2 years will be per standard of care per investigator discretion. * PSA \< 0.2 ng/mL and PSA not trending up: 1. Continue ADT + niraparib/abiraterone acetate plus prednisone for 2 years or until progression or unacceptable toxicity. Therapy beyond 2 years will be per standard of care per investigator discretion OR 2. STOP ADT + niraparib/abiraterone acetate plus prednisone only IF: * C14 PSA \< 0.2 AND not trending up * Subjects not eligible that elect to stop ADT + niraparib/abiraterone acetate plus prednisone, will be removed from protocol treatment and move to follow-up. Subsequent therapy re-initiation will be at the discretion per standard of care.

    Drug: Androgen Deprivation Therapy (ADT) · Drug: Niraparib/Abiraterone Acetate DAT · Drug: Prednisone

Interventions

  • DrugAndrogen Deprivation Therapy (ADT)

    Medical castration per ADT with GnRH agonist or antagonist (or surgical castration per orchiectomy)

  • DrugNiraparib/Abiraterone Acetate DAT

    Drug page: Abiraterone Acetate/NiraparibStudies of Abiraterone Acetate/NiraparibAbiraterone Acetate/Niraparib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Niraparib 200 mg/ Abiraterone acetate 1000 mg orally

    Also known as: Akeega

  • 1000 mg orally

    Also known as: Zytiga

  • 5 mg orally

    Also known as: Rayos, Deltasone, Prednisone Intensol

  • 75 mg/m2 IV

    Also known as: Docefrez, Taxotere

This study also gives NiraparibStudies of NiraparibNiraparib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Rate of participants with PSA decline to < 0.2 ng/ml

    PSA decline is defined as percentage of participants with PSA decline to \< 0.2 ng/ml at 24 weeks of therapy with ADT and niraparib/abiraterone acetate DAT plus prednisone as determined by Cycle 7 Day 1 PSA

    Time frame: 24 weeks

Secondary outcomes

  1. Rate of participants with PSA reduction ≥ 90% (PSA90)

    Percentage of participants with PSA reduction ≥ 90% (PSA90) after 24 weeks of therapy with ADT and niraparib/abiraterone acetate DAT plus prednisone as determined by Cycle 7 Day 1 PSA

    Time frame: 24 weeks

  2. Percentage of participants with PSA decline to < 0.2 ng/ml (Cohort A)

    Percentage of participants with PSA decline to \< 0.2 ng/ml at one year in Cohort A

    Time frame: 12 months

  3. Percentage of participants with PSA decline to < 0.2 ng/ml (Cohort B)

    Percentage of participants with PSA decline to \< 0.2 ng/ml at one year in Cohort B (with additional evaluation of ADT + docetaxel + abiraterone acetate plus prednisone versus ADT niraparib/abiraterone acetate DAT plus prednisone)

    Time frame: 12 months

  4. Overall response rate (ORR)

    Defined as the proportion of subjects achieving either a complete response or a partial response by RECIST 1.1 in subjects with measurable disease and Prostate Cancer Working Group 3 (PCWG 3) criteria for subjects with bone only metastases (1, 2)

    Time frame: 4 years

  5. PSA progression free survival (PFS)

    Defined as interval from start of study treatment to the earliest event of PSA progression or death due to any cause, or the date of last known follow-up without PSA progression, whichever occurs first, according to criteria of the PCWG 3 criteria: for subjects with a decline from baseline, PSA progression is defined as the time from start of therapy to first PSA increase that is ≥ 25% and ≥ 2 ng/mL above nadir which is confirmed by a second value 3 or more weeks later (2)

    Time frame: 4 years

  6. Radiographic progression free survival (rPFS)

    Defined as duration from the start of study treatment to the date of first documentation of rPFS or death due to any cause, whichever occurs first, according RECIST 1.1 in subjects with measurable disease and PCWG3 criteria for subjects with bone only disease (1, 2)

    Time frame: 4 years

  7. Safety of ADT and niraparib/abiraterone acetate DAT plus prednisone

    Safety of ADT + niraparib/abiraterone acetate DAT plus prednisone through evaluation of the incidence and severity of adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs) as assessed by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0).

    Time frame: 4 years

  8. Safety of ADT and docetaxel/abiraterone acetate plus prednisone

    Safety of ADT + docetaxel/abiraterone acetate plus prednisone through evaluation of the incidence and severity of adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs) as assessed by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0).

    Time frame: 4 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2025; primary completion for Jan 2028, 27 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2024
First posted
Apr 30, 2024
StartEst.
Oct 2025
Primary completionEst.
Jan 31, 2028
CompletionEst.
Jan 31, 2029
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06392841
Lead sponsor
Qian Qin
Collaborators
UT Southwestern Comprehensive Cancer Center, Janssen, LP
Responsible party
Qian Qin (Assistant Professor, Hoosier Cancer Research Network) — Sponsor-investigator
First posted
Apr 30, 2024
Start date
Oct 2025 (estimated)
Primary completion
Jan 31, 2028 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Apr 8, 2026

Study contacts

Qian Qin, MD
principal investigator · UT Southwestern Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abiraterone Acetate/Niraparib · Prednisone · Niraparib

Start the discussion